8-K: Tvardi Therapeutics Completes Enrollment in Landmark Phase 2 Trial for IPF Drug TTI-101, Topline Data Expected Q4 2025

Tvardi Therapeutics, Inc. announced the successful completion of enrollment for its Phase 2 clinical trial of TTI-101 in patients with idiopathic pulmonary fibrosis, with key topline data anticipated in the fourth quarter of 2025.

Summary

• Tvardi Therapeutics, Inc. (NASDAQ: TVRD) has completed enrollment for its lead program, TTI-101, in a Phase 2 clinical trial for patients with idiopathic pulmonary fibrosis (IPF).
• The trial, named REVERT IPF, is a randomized, double-blind, placebo-controlled study designed to evaluate TTI-101's safety and lung function (FVC) in IPF patients.
• TTI-101 is an oral, small molecule inhibitor of STAT3, a central mediator in fibrotic signaling pathways.
• Preclinical studies of TTI-101 demonstrated a dual mechanism of action, inhibiting STAT3-driven proliferation while activating T-cells, leading to reduced lung fibrosis and restored lung function.
• Topline data from the REVERT IPF trial is expected to be released in the fourth quarter of 2025.

Sentiment

Score: 8

Explanation: The announcement of completing enrollment in a Phase 2 trial for a lead candidate in a disease with high unmet need is a significant positive milestone for a clinical-stage biopharmaceutical company. While risks inherent to drug development remain, this represents successful execution of a key operational step.

Positives

• Completion of enrollment in a Phase 2 clinical trial marks a significant development milestone for Tvardi's lead therapeutic candidate, TTI-101.
• TTI-101 targets STAT3, a novel mechanism for treating IPF, which addresses a high unmet medical need where current therapies only slow disease progression.
• Preclinical studies showed promising results, including reduced lung fibrosis and restored lung function, suggesting potential for disease reversal or halting.
• The company is on track to deliver topline data in Q4 2025, providing a clear timeline for future updates.

Risks

• Uncertainties are associated with Tvardi's product candidates, including potential delays in the completion of clinical trials.
• Preclinical results may not be indicative of results that will be observed in clinical trials.
• Tvardi has incurred significant net losses since its inception.
• The company's ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development is subject to risk.
• The timing of the availability of data from Tvardi's clinical trials is uncertain.
• The outcome of preclinical testing and clinical trials, including the ability to satisfy relevant governmental or regulatory requirements, is not guaranteed.
• There is a requirement for additional capital to continue advancing product candidates, which may not be available on favorable terms or at all.
• Tvardi's ability to attract, hire, and retain skilled executive officers and employees is crucial.
• The company's ability to protect its intellectual property and proprietary technologies is a risk.
• Reliance on third parties, contract manufacturers, and contract research organizations poses risks.
• Tvardi may be adversely affected by other economic, business, or competitive factors.
• Risks are associated with changes in applicable laws or regulations.

Future Outlook

Tvardi Therapeutics anticipates releasing topline data from its Phase 2 REVERT IPF trial in the fourth quarter of 2025. The company is optimistic that TTI-101's unique dual mechanism of action, which showed promising results in preclinical studies, will translate into clinical benefits for patients suffering from idiopathic pulmonary fibrosis, a disease with significant unmet medical needs.

Management Comments

• Dr. Imran Alibhai, Chief Executive Officer of Tvardi, stated: "We are thrilled to announce the completion of enrollment in our Phase 2 trial of TTI-101 for idiopathic pulmonary fibrosis, our lead clinical indication. This marks a major milestone in our mission to address a disease with high unmet need where current therapies only slow progression but fall short of halting or reversing fibrosis."
• Dr. Alibhai also commented: "TTI-101 has demonstrated a unique and powerful dual mechanism of action: inhibiting STAT3-driven proliferation while activating T-cells, resulting in reduced lung fibrosis and restored lung function in preclinical studies. We are energized by the potential of TTI-101 and are eager to see whether the preclinical studies results translate into our Phase 2 REVERT IPF trial. Topline data is expected in Q4 of this year."

Industry Context

Idiopathic Pulmonary Fibrosis (IPF) is a severe, chronic, progressive, and debilitating lung disease with an unknown cause and poor prognosis. Current therapies for IPF primarily focus on slowing disease progression but do not halt or reverse fibrosis. Tvardi's TTI-101 targets STAT3, a central mediator in fibrotic signaling pathways, representing a novel approach in a therapeutic area where existing treatments have limitations and no other therapies have specifically interrogated STAT3.

Comparison to Industry Standards

• The document highlights that while several efforts are underway to discover novel ways to treat IPF, none have specifically interrogated STAT3, suggesting Tvardi's approach with TTI-101 is unique within the current landscape of IPF drug development.
• The document does not provide specific comparable companies, projects, or results to benchmark TTI-101 against, beyond stating that current therapies only slow progression.

Stakeholder Impact

• Shareholders: Positive impact due to the achievement of a significant clinical development milestone, potentially de-risking the TTI-101 program and providing a clear timeline for future data.
• Patients with IPF: Potential positive impact as TTI-101 represents a novel therapeutic approach that aims to not just slow, but potentially halt or reverse fibrosis, addressing a high unmet medical need.
• Employees: Positive impact from the successful progression of a key clinical program, reinforcing the company's mission and development efforts.

Next Steps

• Analysis and readout of topline data from the REVERT IPF Phase 2 clinical trial, anticipated in the fourth quarter of 2025.

Key Dates

Keywords

Tvardi Therapeutics, TTI-101, Idiopathic Pulmonary Fibrosis, IPF, STAT3 inhibitor, Phase 2 clinical trial, REVERT IPF, Biopharmaceutical, Clinical-stage, Fibrosis-driven diseases, Lung function, FVC